copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Homepage - RAPT Therapeutics RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases Our cutting-edge science is fully focused on developing therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammatory and immunologic diseases, and improve and empower countless lives Join us in our quest
About Us - RAPT Therapeutics RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologic diseases Utilizing our deep and proprietary expertise in immunology, we develop novel molecules that are designed to modulate the critical immune responses underlying these diseases Our
Pipeline - RAPT Therapeutics RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases Utilizing our deep and proprietary expertise in immunology, we are developing novel molecules that are designed to modulate the critical immune responses underlying these diseases
Science - RAPT Therapeutics RPT904 long-acting anti-IgE antibody RPT904 is a novel half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobulin E (IgE), a key driver of allergic diseases We plan to develop RPT904 initially as a treatment for food allergy (FA) and chronic spontaneous urticaria (CSU) and potentially other allergic inflammatory diseases in the future In a first-in-human study in
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of . . . RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies October 27, 2025 Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven condition RAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRANCISCO
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock In addition, RAPT has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of its common stock at the public offering price, less underwriting discounts and commissions All of the shares of common stock are being offered by RAPT
FLX Bio Announces Name Change to RAPT Therapeutics - RAPT Therapeutics SOUTH SAN FRANCISCO, Calif --( BUSINESS WIRE )--FLX Bio, a clinical-stage, immunology-based biopharmaceutical company, today announced it has changed its name to RAPT Therapeutics, Inc , to more accurately represent the company’s dedication and focused efforts to develop and commercialize oral
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive . . . About RAPT Therapeutics, Inc RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases
Careers - RAPT Therapeutics At RAPT Therapeutics, we believe in bringing our whole selves to work each day, which requires important work-life balance We encourage all employees to rejuvenate by sharing experiences with colleagues and also friends and family We enjoy events each quarter including BBQs, movie screenings, offsite retreats and holiday parties In addition, we partner with key organizations around the Bay